Fluvoxamine identified as a potential treatment for eye inflammation
A lipid-sensing receptor GPR183 is found to drive autoimmune uveitis through a specific signaling pathway.
Fluvoxamine (FLV) may be repurposed to treat autoimmune uveitis (AU). This condition is a leading cause of irreversible blindness.
Researchers used single-cell RNA sequencing and multilayered metabolomic profiling. They studied patients with AU and experimental AU models.
The lipid-sensing G protein-coupled receptor GPR183 acts as a key immunometabolic regulator. It is found in pathogenic CD4+ T cells.
GPR183 activation promotes son-of-sevenless-dependent KRAS activation. This leads to copper overload-induced mitochondrial oxidative stress and metabolic rewiring toward glycolysis.
Fluvoxamine (FLV) acts as a direct GPR183 antagonist. In models of uveitis and colitis, FLV attenuated GPR183-KRAS signaling and dampened pathogenic T H 17 cell responses.
These findings support repurposing FLV for AU and other autoimmune inflammatory disorders. This could help alleviate tissue inflammation.
Key facts
- GPR183 is a lipid-sensing G protein-coupled receptor.
- Fluvoxamine (FLV) is a direct GPR183 antagonist.
- GPR183-KRAS signaling promotes T H 17 cell pathogenicity.